Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Bookmark and Share
Published: 2 Jun 2019
Views: 516
Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Dr Christopher Sweeney presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the ENZAMET trial.

This was a phase III internationally randomised trial in which patients with mHSPC who received testosterone suppression were also given enzalutamide or standard nonsteroidal androgen receptor inhibitors, with those receiving enzalutamide surviving longer after 3 years (80% to 72%).

Watch the interview here.

Watch a comment from Dr Neeraj Agarwal here.